Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.

Lung cancer (Amsterdam, Netherlands) - 1 Dec 2020

Ohashi Kadoaki, Ninomiya Kiichiro, Yoshioka Hiroshige, Bessho Akihiro, Shibayama Takuo, Aoe Keisuke, Ishikawa Nobuhisa, Kozuki Toshiyuki, Kawai Haruyuki, Kuyama Shoichi, Miyoshi Seigo, Fujitaka Kazunori, Obata Hideto, Tsubata Yukari, Awaya Yoshikazu, Inoue Masaaki, Inoue Koji, Horita Naokatsu, Yanai Hiroyuki, Hotta Katsuyuki, Kiura Katsuyuki

Abstract excerpt

OBJECTIVES: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 33096420
DOI: 10.1016/j.lungcan.2020.09.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.PMID 33096420Read ↗

Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan.Semantic proximity Read ↗

Treatment Outcome and Clinical Characteristics of HER2 Mutated Advanced Non-Small Cell Lung Cancer Patients in ChinaSemantic proximity Read ↗

Real-world therapeutic strategies and survival outcomes in advanced HER2 -mutant non-small cell lung cancer.Semantic proximity Read ↗

Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.Semantic proximity Read ↗

Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.Semantic proximity Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.Semantic proximity Read ↗

Real-World Patient Characteristics, Mutational Landscape, and Outcomes in Advanced/Metastatic HER2-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.